Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes.
Saved in:
| Title: | Phase I Clinical Trial of Islet Antigen-Specific Plasmid Coexpressing Tolerogenic Proteins Demonstrates Safety in Adults With Type 1 Diabetes. |
|---|---|
| Authors: | Greenbaum CJ; Center for Interventional Immunology, Benaroya Research Institute, Seattle, WA., Long SA; Center for Translational Immunology, Benaroya Research Institute, Seattle, WA., Gitelman SE; University of California, San Francisco, San Francisco, CA., Gaglia JL; Joslin Diabetes Center, Harvard Medical School, Boston, MA., Daniels M; Division of Endocrinology and Diabetes, Children's Hospital of Orange County, Orange, CA., Brusko TM; Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL., Lord S; Center for Interventional Immunology, Benaroya Research Institute, Seattle, WA., Bundy BN; Health Informatics Institute, University of South Florida, Tampa, FL., Krischer JP; Health Informatics Institute, University of South Florida, Tampa, FL., Haller MJ; Department of Pediatrics, Diabetes Institute, College of Medicine, University of Florida, Gainesville, FL., Steck AK; Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO., DiMeglio LA; Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Indiana University, Indianapolis, IN., Evans-Molina C; Division of Pediatric Endocrinology and Diabetology, Department of Pediatrics, Indiana University, Indianapolis, IN., Moran A; Department of Pediatrics, University of Minnesota, Minneapolis, MN., Prahalad P; Division of Endocrinology and Diabetes, Department of Pediatrics, Stanford University, Stanford, CA., Wilson DM; Division of Endocrinology and Diabetes, Department of Pediatrics, Stanford University, Stanford, CA., Russell WE; Departments of Pediatrics and Cell and Developmental Biology, Vanderbilt University Medical Center, Nashville, TN., Sherr JL; Division of Pediatric Endocrinology, Yale University School of Medicine, New Haven, CT., Raskin P; Department of Pediatrics, University of Texas Southwestern, Dallas, TX., Clements MA; Division of Pediatric Endocrinology, Children's Mercy Hospital, University of Missouri-Kansas City, Kansas City, MO., Moore WV; Division of Pediatric Endocrinology, Children's Mercy Hospital, University of Missouri-Kansas City, Kansas City, MO., Libman I; Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA., Wassermann K; Novo Nordisk A/S, Søborg, Denmark., von Herrath M; Novo Nordisk A/S, Søborg, Denmark., Bergholdt R; Novo Nordisk A/S, Søborg, Denmark., Hastrup H; Novo Nordisk A/S, Søborg, Denmark., Kobernat SE; Center for Translational Immunology, Benaroya Research Institute, Seattle, WA., Kus AM; Center for Translational Immunology, Benaroya Research Institute, Seattle, WA., Tung LW; Center for Systems Biology, Benaroya Research Institute, Seattle, WA., Goland RS; Departments of Medicine and Pediatrics, Columbia University, New York, NY., Herold KC; Departments of Immunobiology and Internal Medicine, Yale University, New Haven, CT. |
| Corporate Authors: | Type 1 Diabetes TrialNet Study Group* |
| Source: | Diabetes [Diabetes] 2026 Mar 01; Vol. 75 (3), pp. 506-518. |
| Publication Type: | Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial |
| Journal Info: | Publisher: American Diabetes Association Country of Publication: United States NLM ID: 0372763 Publication Model: Print Cited Medium: Internet ISSN: 1939-327X (Electronic) Linking ISSN: 00121797 NLM ISO Abbreviation: Diabetes Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1939-327X |
|---|---|
| DOI: | 10.2337/db25-0777 |
